Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2022-08-17

Clinical Trial Update: Zanubrutinib-rituximab(ZR) in Patients With Newly Diagnosed Untreated Mantle Cell Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial update for Zanubrutinib combined with rituximab in patients with newly diagnosed untreated mantle cell lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Zanubrutinib-rituximab (ZR)

Snippet

Sponsor: The First Affiliated Hospital of Soochow University | Conditions: Untreated Mantle Cell Lymphoma | Phase 2 | Status: UNKNOWN